Curis INC 8-K filings

Curis, Inc. has received notification from Nasdaq that it has regained compliance with the Bid Price Rule and will be subject to a one-year monitoring period.

Curis, Inc. has filed a certificate of amendment to its Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split of its common stock, effective July 2, 2026.

Curis, Inc. has filed an amendment to its Form 8-K to announce the expected market effective date for its previously announced reverse stock split.

Curis, Inc. announced its stockholders approved amendments to its Restated Certificate of Incorporation to effect a reverse stock split, with the Board subsequently approving a 1-for-20 ratio.

Curis, Inc. shareholders have voted to approve a reverse stock split at a ratio between 1-for-5 and 1-for-25.

Curis, Inc. announced its first-quarter 2026 business update and financial results, highlighting progress in emavusertib clinical trials for lymphoma and leukemia, alongside a net loss of $24.2 million.

Curis, Inc. has received a delisting notice from Nasdaq due to its common stock closing below the $1.00 minimum bid price requirement for 30 consecutive business days.

Curis, Inc. announced its fourth quarter and full-year 2025 financial results, alongside significant clinical progress for its lead drug candidate, emavusertib, and a recent $80.8 million private placement.

Curis, Inc. stockholders approved a significant increase in authorized common stock and a new 2026 Incentive Plan at a Special Meeting held on March 17, 2026.

Curis, Inc. announced it has regained compliance with Nasdaq listing rules but will be subject to a one-year discretionary panel monitor.

Curis, Inc. announced a private placement raising $20.2 million initially, with potential for up to $80.8 million, to fund R&D and operations, while addressing Nasdaq listing concerns.

Curis, Inc. filed an amended 8-K to include pro forma financial information detailing the impact of its Erivedge business sale, including a $2.5 million upfront payment and extinguishment of a $28.6 million royalty liability.

Curis, Inc. announced the sale of its Erivedge royalty interest for $2.5 million, extinguished a related liability, and provided a Q3 2025 business update, including clinical progress and Nasdaq listing efforts.

Curis, Inc. has received an extension until November 14, 2025, from the Nasdaq Hearings Panel to regain compliance with the $35 million market value of listed securities requirement, avoiding immediate delisting.

Curis, Inc. received a delisting notice from Nasdaq due to non-compliance with the minimum market value requirement and intends to appeal the decision.

Curis, Inc. filed a prospectus supplement to offer and sell up to $8.1 million in common stock through an at-the-market offering.

Curis, Inc. announced its second quarter 2025 financial results, reporting a reduced net loss and increased revenue, alongside significant clinical progress for its lead asset, emavusertib, in lymphoma and leukemia studies.

Curis, Inc. has announced a $7.0 million registered direct offering and concurrent private placement of common stock and warrants, aiming to fund operations into the first quarter of 2026 and advance its emavusertib clinical programs.

Curis Inc. stockholders approved an amendment to the company's certificate of incorporation to increase authorized shares and an amendment to the stock incentive plan at the 2025 Annual Meeting.

Curis, Inc. announced its Q1 2025 financial results, highlighted by the appointment of Dr. Ahmed Hamdy as Chief Medical Officer and progress in emavusertib's development for PCNSL.

Curis, Inc. reports successful discussions with the FDA and EMA regarding accelerated approval for emavusertib in PCNSL, along with fourth quarter 2024 financial results and a recent $10 million capital raise.

Curis Inc. enters into a securities purchase agreement for a $10 million offering and provides an update on its TakeAim Lymphoma study for emavusertib.

Curis, Inc. received a notice from Nasdaq stating that it is not in compliance with the minimum market value requirement, potentially leading to delisting.

Curis Inc. reported its third quarter 2024 financial results, highlighted by progress in its clinical programs and a recent capital raise.

Curis Inc. has secured $12.1 million through a registered direct offering and concurrent private placement to fund research, development, and general corporate purposes.

Curis reported its second quarter 2024 financial results, highlighted by a net loss of $11.8 million and the European Commission granting Orphan Drug Designation to emavusertib for PCNSL.

Curis Inc. has increased authorized shares and streamlined operations, including a workforce reduction, to focus on key combination studies.

Curis, Inc. released updated data from its TakeAim Leukemia study, showcasing encouraging results for emavusertib as a monotherapy in relapsed/refractory Acute Myelogenous Leukemia (AML) patients with specific genetic mutations.

Curis, Inc. reported its first quarter 2024 financial results, including a net loss of $11.9 million, and provided an update on its clinical programs, including upcoming data presentations at major oncology conferences.

Curis, Inc. announced its full year and fourth quarter 2023 financial results, highlighting clinical trial progress and a cash runway into 2025.